NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
Clinical Trials
8 trialsNCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT03466216 2025-06-10
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC
Phase 1 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04893759 2025-04-17
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated